Vanda Pharmaceuticals (VNDA) Stock Price, Quote & News

Company Profile

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for prev...

Industry: Biotechnology

Sector: Healthcare

Phone: 202 734 3400

Website: www.vandapharma.com

Address:

2200 Pennsylvania Avenue NW, Suite 300E, Washington, United States

cloudhedge May. 13 at 3:22 PM

$VNDA - Keep on radar Commercial launch approaching. Vanda Pharmaceuticals announced FDA approval of BYSANTI™ (milsaperidone) for Bipolar I Disorder and Schizophrenia. As a New Chemical Entity (NCE), this treatment introduces a new clinical pathway in psychiatric innovation. Follow me 👉 @cloudhedge for real-time updates and everything. Let’s make moves!

0 · Reply

Massimo21 May. 13 at 1:04 PM

$VNDA The pattern suggests that the next pool of takeover targets will be drawn from U.S. biotechs that have recently won FDA approval. In recent months, the FDA has approved Denali Therapeutics’ Hunter syndrome drug, Omeros’ treatment for a hematopoietic stem cell transplant complication, two Vanda Pharmaceuticals products and Sentynl Therapeutics’ Menkes disease therapy. https://www.biospace.com/business/mid-sized-european-drugmakers-are-snapping-up-us-biotechs-will-the-surge-continue

0 · Reply

Rawbinhood May. 12 at 9:25 PM

$VNDA Some Tutes have been increasing holdings

0 · Reply

Rawbinhood May. 12 at 9:22 PM

$VNDA State Street really increase their positions!!!

0 · Reply

MattyMoMo May. 12 at 8:09 PM

$VNDA I'm just flabbergasted that these "analysts" never ask a challenging question on the conference call... like: When do you think you will become profitable?

0 · Reply

TomMac64 May. 12 at 7:09 PM

$VNDA Don’t know if anyone has noticed but this is going ……

0 · Reply

cb28 May. 12 at 6:52 PM

$VNDA not sure this is gonna drop below 5 ive been patient.

1 · Reply

Brandon4020 May. 11 at 1:40 PM

$VNDA

1 · Reply

MattyMoMo May. 11 at 12:23 PM

$VNDA Did they announce the buyout yet? 😂

2 · Reply

Mike22332233 May. 10 at 2:46 AM

$SLS is by far my top holding, with that position consisting in about a 33% equal weight in its common stock and in '27 Leaps and in '28 Leaps .... my other post had the first 5 of my top 10 holdings …. and here is the second half of that list: ,,,,$ATER, $LSTA, $VNDA and $INBX ... FOLLOW my posts to see all DD and my expected returns on these very special situations ... YOU might like what you see !!!

0 · Reply

Vanda Pharmaceuticals price target lowered to $21 from $24 at H.C. Wainwright

May 7, 2026, 6:44 PM EDT - 5 days ago

Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences

2026-05-07T01:52:21.000Z - 6 days ago

Vanda Pharmaceuticals reports Q1 EPS (82c) vs. (50c) last year

2026-05-07T01:50:55.000Z - 6 days ago

Vanda Pharmaceuticals raises FY26 revenue view to $240M-$290M from $230-$260M

May 6, 2026, 4:30 PM EDT - 6 days ago

Vanda Pharmaceuticals Earnings Call Transcript: Q1 2026

May 6, 2026, 4:01 PM EDT - 6 days ago

Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results

2026-05-04T12:46:08.000Z - 9 days ago

Vanda Pharmaceuticals announces U.S. commercial availability of Nereus

May 4, 2026, 8:00 AM EDT - 9 days ago

Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years

2026-05-01T20:40:19.000Z - 11 days ago

Vanda Pharmaceuticals announces commercial availability for Nereus

Apr 29, 2026, 4:30 PM EDT - 13 days ago

Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

Apr 28, 2026, 7:12 PM EDT - 14 days ago

Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence

ANAB

Apr 22, 2026, 5:13 PM EDT - 20 days ago

Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors

2026-04-09T15:10:15.000Z - 4 weeks ago

Vanda calls on FDA to remove proposal extending drug review timelines

Apr 9, 2026, 11:02 AM EDT - 4 weeks ago

Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines

2026-04-08T20:50:15.000Z - 4 weeks ago

Vanda Pharmaceuticals initiates trial of tradipitant in GLP-1-caused vomiting

Apr 8, 2026, 4:44 PM EDT - 4 weeks ago

Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists

Mar 19, 2026, 4:34 PM EDT - 7 weeks ago

Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods

Mar 11, 2026, 2:15 PM EDT - 2 months ago

Vanda Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026

2026-03-05T11:11:50.000Z - 2 months ago

Vanda Pharmaceuticals initiated with a Buy at Truist

2026-03-03T13:05:54.000Z - 2 months ago

Vanda Pharmaceuticals: FDA grants hearing to review sNDA for Hetlioz

Mar 3, 2026, 8:01 AM EST - 2 months ago

Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years

Feb 26, 2026, 4:35 PM EST - 2 months ago

Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference

2026-02-25T13:35:25.000Z - 2 months ago

Vanda Pharmaceuticals price target raised to $17 from $14 at B. Riley

2026-02-25T12:23:26.000Z - 2 months ago

Vanda announces FDA accepted BLA for imsidolimab

Feb 25, 2026, 7:18 AM EST - 2 months ago

Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

ANAB

Feb 23, 2026, 10:28 AM EST - 2 months ago

Vanda Pharmaceuticals stock's explosive rally may be more hype than substance

2026-02-23T14:46:56.000Z - 2 months ago

Unusually active option classes on open February 23rd

FRO FSLY GRAL OPEN QUBT SLS VKTX

2026-02-23T11:10:11.000Z - 2 months ago

Vanda Pharmaceuticals price target raised to $24 from $22 at H.C. Wainwright

Feb 20, 2026, 6:03 PM EST - 2 months ago

US FDA approves Vanda's psychiatric drug

Feb 20, 2026, 5:59 PM EST - 2 months ago

Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation

Feb 11, 2026, 4:30 PM EST - 3 months ago

Vanda Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 11, 2026, 4:01 PM EST - 3 months ago

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 4, 2026, 6:01 PM EST - 3 months ago

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

Jan 15, 2026, 12:00 PM EST - 4 months ago

Vanda Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 9:31 AM EST - 4 months ago

Vanda and Exante Data Combine in Strategic Merger

Jan 8, 2026, 7:00 AM EST - 4 months ago

Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder

Dec 31, 2025, 10:57 AM EST - 4 months ago

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval

Dec 30, 2025, 6:30 PM EST - 4 months ago

US FDA approves Vanda Pharmaceuticals' motion sickness drug

Dec 30, 2025, 6:13 PM EST - 4 months ago

Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness

Dec 15, 2025, 7:00 AM EST - 5 months ago

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

ANAB

Dec 11, 2025, 5:02 PM EST - 5 months ago

Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference

Dec 4, 2025, 4:21 PM EST - 5 months ago

FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness

Nov 28, 2025, 7:00 AM EST - 5 months ago

Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness

Nov 17, 2025, 6:37 PM EST - 6 months ago

Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting

Nov 12, 2025, 4:40 PM EST - 6 months ago

Vanda Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Nov 5, 2025, 5:00 PM EST - 6 months ago

Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference

Oct 29, 2025, 4:30 PM EDT - 6 months ago

Vanda Pharmaceuticals Earnings Call Transcript: Q3 2025

Oct 29, 2025, 4:01 PM EDT - 6 months ago

Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results

Oct 22, 2025, 4:30 PM EDT - 7 months ago

Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025

Oct 8, 2025, 8:00 AM EDT - 7 months ago

Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena

Oct 1, 2025, 5:02 PM EDT - 7 months ago

Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration

Sep 25, 2025, 8:00 AM EDT - 8 months ago

Vanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"

Sep 9, 2025, 8:30 AM EDT - 8 months ago

Vanda Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 4:30 PM EDT - 8 months ago

Vanda Pharmaceuticals Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 3:55 PM EDT - 8 months ago

Vanda Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Aug 28, 2025, 5:23 PM EDT - 9 months ago

Vanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences

Aug 28, 2025, 7:00 AM EDT - 9 months ago

Vanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera

Aug 21, 2025, 4:40 PM EDT - 9 months ago

Vanda Seeks FDA Commissioner Review of Outgoing CDER Director's Decision to Uphold Approval of Two Generic Versions of Hetlioz®

Aug 18, 2025, 7:00 AM EDT - 9 months ago

In a Major Win for Vanda, a Federal Appeals Court Overturns FDA's Order Denying Approval of Hetlioz for the Treatment of Jet Lag Disorder

Jul 31, 2025, 8:00 AM EDT - 10 months ago

Vanda Pharmaceuticals Earnings Call Transcript: Q2 2025

Jul 31, 2025, 7:30 AM EDT - 10 months ago

Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 4:45 PM EDT - 10 months ago

Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025

Jun 10, 2025, 8:00 AM EDT - 1 year ago

Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S

May 27, 2025, 9:00 AM EDT - 1 year ago

Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

May 16, 2025, 5:30 PM EDT - 1 year ago

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Vanda Pharmaceuticals Earnings Call Transcript: Q1 2025

May 7, 2025, 4:01 PM EDT - 1 year ago

Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

May 5, 2025, 8:00 AM EDT - 1 year ago

Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026

May 2, 2025, 8:46 AM EDT - 1 year ago

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025

Apr 23, 2025, 3:52 PM EDT - 1 year ago

FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA

Apr 7, 2025, 8:00 AM EDT - 1 year ago

Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting

cloudhedge May. 13 at 3:22 PM

0 · Reply

Massimo21 May. 13 at 1:04 PM

0 · Reply

Rawbinhood May. 12 at 9:25 PM

$VNDA Some Tutes have been increasing holdings

0 · Reply

Rawbinhood May. 12 at 9:22 PM

$VNDA State Street really increase their positions!!!

0 · Reply

MattyMoMo May. 12 at 8:09 PM

$VNDA I'm just flabbergasted that these "analysts" never ask a challenging question on the conference call... like: When do you think you will become profitable?

0 · Reply

TomMac64 May. 12 at 7:09 PM

$VNDA Don’t know if anyone has noticed but this is going ……

0 · Reply

cb28 May. 12 at 6:52 PM

$VNDA not sure this is gonna drop below 5 ive been patient.

1 · Reply

Brandon4020 May. 11 at 1:40 PM

$VNDA

1 · Reply

MattyMoMo May. 11 at 12:23 PM

$VNDA Did they announce the buyout yet? 😂

2 · Reply

Mike22332233 May. 10 at 2:46 AM

0 · Reply

Mike22332233 May. 8 at 11:39 PM

$VNDA Hearing 2 BP firms are looking at maybe making a VNDA BO Offer, but first wanted the QTR results out to see the current financial status and cash on hand ... and also if stock dropped because of results (as it did), then offer would look that much better !!! Maybe, we can hope for some movement in that offer in the next 10 days ....

5 · Reply

MarkM May. 8 at 9:51 PM

$VNDA It boggles my mind that this stock has so few followers on ST. Even for swing traders, the setups are quite actionable and can yield profits with manageable opportunity cost. Long term, this company is a pharmaceutical industry winner--they have come much, much farther than most in a very difficult therapeutic space. Surprised more eyes are not on this ticker on ST. Personally, I'll be looking for more gems like this one out in Bio world.

3 · Reply

TomMac64 May. 8 at 9:29 PM

$VNDA If you need someone to tell you there is ZERO correlation between price movement and a great (company) stock you really shouldn’t be trading … play the indexes !

1 · Reply

Mike22332233 May. 8 at 9:10 PM

$VNDA Look and follow my posts to see details !!!

1 · Reply

Mike22332233 May. 8 at 9:08 PM

$VNDA Hearing movement on BO offer !!!!

1 · Reply

jacckkmm May. 8 at 8:40 PM

$VNDA Monday could be fun?

1 · Reply

Sunhouse9 May. 8 at 8:27 PM

$VNDA some activity AH..😀

0 · Reply

Cmhatwell May. 8 at 6:40 PM

$VNDA merger monday

0 · Reply

BullMaven May. 8 at 3:04 PM

$VNDA

0 · Reply

TomMac64 May. 8 at 11:01 AM

$VNDA Couldn’t agree more !

0 · Reply

biotechie53 May. 8 at 7:17 AM

$VNDA They still have $200MM and increasing cash flow from sales. They can manage a few more quarters. It is pretty dilutive to raise new money at this low stock price.

2 · Reply

biotechie53 May. 8 at 6:58 AM

$VNDA They will not be able to make this work. They have drugs with fragmented sales that require large sales force. Also require funding for the pipeline. Ideal situation for shareholders is a larger player to buy this company. If they do not want to sell, a $12-15 hostile offer may work now at this low stock price. There seem to be many frustrated shareholders here. LLU or PFE deal may be ideal. They seem to have a relationship with LLY.

0 · Reply

Market Cap	377.05M
Revenue (ttm)	216.11M
Net Income (ttm)	-220.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-102.02%
Debt to Equity Ratio	0.00

Volume	591,923
Avg Vol	1,539,754
Day's Range	N/A - N/A
Shares Out	60.14M
Stochastic %K	17%
Beta	0.65
Analysts	Strong Sell
Price Target	$14.90